Free tool

GLP-1 Supply and Shortage Tracker

On November 18, 2026, the FDA listed no shortage of any strength of Ozempic®, Wegovy®, Mounjaro® or Zepbound®. It listed Saxenda® and Victoza® with limited availability.1 This page asks the FDA again each time it loads.

Shortage status by brand and strength

Saved copy, not liveSaved on November 18, 2026. Statuses may have changed since then.

2 of these 7 brands have a strength on FDA’s shortage list: Saxenda, Victoza.

Strength and formFDA shortage status
Ozempic semaglutide Not on FDA’s shortage list
0.68 mg/1 mL Pen for 0.25 mg and 0.5 mg dosesNot on FDA’s shortage list
1.34 mg/1 mL Pen for 1 mg dosesNot on FDA’s shortage list
2.68 mg/1 mL Pen for 2 mg dosesNot on FDA’s shortage list
1.5 mg TabletNot on FDA’s shortage list
4 mg TabletNot on FDA’s shortage list
9 mg TabletNot on FDA’s shortage list
Wegovy semaglutide Not on FDA’s shortage list
0.25 mg/0.5 mL Single-dose penNot on FDA’s shortage list
0.5 mg/0.5 mL Single-dose penNot on FDA’s shortage list
1 mg/0.5 mL Single-dose penNot on FDA’s shortage list
1.7 mg/0.75 mL Single-dose penNot on FDA’s shortage list
2.4 mg/0.75 mL Single-dose penNot on FDA’s shortage list
7.2 mg/0.75 mL Single-dose penNot on FDA’s shortage list
1.5 mg TabletNot on FDA’s shortage list
4 mg TabletNot on FDA’s shortage list
9 mg TabletNot on FDA’s shortage list
25 mg TabletNot on FDA’s shortage list
Mounjaro tirzepatide Not on FDA’s shortage list
2.5 mg/0.5 mL Single-dose penNot on FDA’s shortage list
5 mg/0.5 mL Single-dose penNot on FDA’s shortage list
7.5 mg/0.5 mL Single-dose penNot on FDA’s shortage list
10 mg/0.5 mL Single-dose penNot on FDA’s shortage list
12.5 mg/0.5 mL Single-dose penNot on FDA’s shortage list
15 mg/0.5 mL Single-dose penNot on FDA’s shortage list
Zepbound tirzepatide Not on FDA’s shortage list
2.5 mg/0.5 mL Single-dose pen or vialNot on FDA’s shortage list
5 mg/0.5 mL Single-dose pen or vialNot on FDA’s shortage list
7.5 mg/0.5 mL Single-dose pen or vialNot on FDA’s shortage list
10 mg/0.5 mL Single-dose pen or vialNot on FDA’s shortage list
12.5 mg/0.5 mL Single-dose pen or vialNot on FDA’s shortage list
15 mg/0.5 mL Single-dose pen or vialNot on FDA’s shortage list
10 mg/2.4 mL KwikPen, four 2.5 mg dosesNot on FDA’s shortage list
20 mg/2.4 mL KwikPen, four 5 mg dosesNot on FDA’s shortage list
30 mg/2.4 mL KwikPen, four 7.5 mg dosesNot on FDA’s shortage list
40 mg/2.4 mL KwikPen, four 10 mg dosesNot on FDA’s shortage list
50 mg/2.4 mL KwikPen, four 12.5 mg dosesNot on FDA’s shortage list
60 mg/2.4 mL KwikPen, four 15 mg dosesNot on FDA’s shortage list
Saxenda liraglutide On FDA’s shortage list
6 mg/1 mL Multi-dose penOn FDA’s shortage list
  • Availability: Limited Availability. Reason given to the FDA: Discontinuation of the manufacture of the drug. Record updated 09/22/2026. FDA record: Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15).
To be discontinued. The FDA also has a discontinuation record for Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) (record dated 08/25/2026).
Victoza liraglutide On FDA’s shortage list
6 mg/1 mL Multi-dose penOn FDA’s shortage list
  • Availability: Limited Availability. Reason given to the FDA: Delay in shipping of the drug. Record updated 09/22/2026. FDA record: Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12).
  • Availability: Limited Availability. Reason given to the FDA: Delay in shipping of the drug. Record updated 09/22/2026. FDA record: Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13).
Trulicity dulaglutide Not on FDA’s shortage list
0.75 mg/0.5 mL Single-dose penNot on FDA’s shortage list
1.5 mg/0.5 mL Single-dose penNot on FDA’s shortage list
3 mg/0.5 mL Single-dose penNot on FDA’s shortage list
4.5 mg/0.5 mL Single-dose penNot on FDA’s shortage list

Strengths come from the current labels.2 Label presentations we could not confirm are stocked (Ozempic and Wegovy syringes, Wegovy FlexTouch, Mounjaro vials and KwikPen, Zepbound multi-dose vial) have no row unless the FDA lists one.

10 other FDA records for these ingredients
FDA recordFDA status
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03) Hikma Pharmaceuticals USA, Inc.On FDA’s shortage list
  • Availability: Available. Record updated 10/14/2026.
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02) Hikma Pharmaceuticals USA, Inc.On FDA’s shortage list
  • Availability: Available. Record updated 10/14/2026.
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) Novo Nordisk, Inc.On FDA’s shortage list
  • Availability: Available. Record updated 09/22/2026.
Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) Novo Nordisk, Inc.To be discontinued
  • Record updated 06/04/2026.
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) Novo Nordisk, Inc.On FDA’s shortage list
  • Availability: Available. Record updated 09/22/2026.
Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) Novo Nordisk, Inc.To be discontinued
  • Record updated 06/04/2026.
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84) Meitheal Pharmaceuticals, Inc.On FDA’s shortage list
  • Availability: Available. Record updated 08/27/2026.
Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) Novo Nordisk, Inc.To be discontinued
  • Record updated 06/04/2026.
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85) Meitheal Pharmaceuticals, Inc.On FDA’s shortage list
  • Availability: Available. Record updated 08/27/2026.
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46) Teva Pharmaceuticals USA, Inc.To be discontinued
  • Record updated 05/14/2026.

The FDA’s own pages

Data provided by the U.S. Food and Drug Administration (https://open.fda.gov).3 Its notice on this data: “Do not rely on openFDA to make decisions regarding medical care.”1 The table repeats FDA records, not any pharmacy’s stock.

Dose hard to find? A licensed Zealthy provider can review your options.

Get Started

How to read the GLP-1 shortage table

Each row is one strength of one brand, in the mg per mL form that FDA shortage records use. For multi-dose pens that is the concentration: Ozempic 0.68 mg/1 mL is the pen for 0.25 mg and 0.5 mg doses.2

  • Not on FDA’s shortage list: the FDA has no “Current” record for that strength.
  • On FDA’s shortage list: it has one. The row repeats its availability, reason and date, which manufacturers mostly supply.4
  • To be discontinued: a separate FDA record, shown as a note under the brand.

The data is every record openFDA, the FDA’s public data service, holds for semaglutide, tirzepatide, liraglutide and dulaglutide.1 The line above the table says whether it is live, with the time it was fetched, or the copy saved on November 18, 2026.

GLP-1 shortage timeline: 2022 to 2026

Both shortages are over. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved on February 21, 2025.5

DateWhat happened
March 2022Wegovy is added to the FDA shortage list.6
August 2022Ozempic is added.6
December 15, 2022Tirzepatide injection is added.7
July 18, 2023Liraglutide injection (Victoza, Saxenda) is first posted. It is still listed.8
October 2, 2024Tirzepatide shortage declared resolved, then confirmed on December 19, 2024 after a lawsuit.5,7
February 21, 2025Semaglutide injection shortage declared resolved.5,6
August 25, 2026An FDA record lists Saxenda as to be discontinued. Novo Nordisk expects its last wholesaler shipments in late January 2027.1,9
November 18, 2026No shortage record for semaglutide injection, tirzepatide or dulaglutide (Trulicity®). Victoza and Saxenda show limited availability.1

What an FDA shortage listing means at your pharmacy

A listing describes supply from the manufacturer, not the shelf at your pharmacy. “Current” means the FDA knows of a supply problem and is working with the companies involved.4 A listed strength may still be on the shelf, and an unlisted one can be out at a single store.

Read the availability line too. A maker can report “Available” under a current listing. That is its own report, not an FDA finding that the shortage is over.5

What to do if your GLP-1 dose is hard to find

Start with your pharmacy, then your provider, before your last dose.

  • Ask your pharmacy when your strength is expected.
  • Try a second pharmacy. Your provider can send the prescription there.
  • Message your provider early. Do not change strength, split or stretch doses, or switch medications on your own.
  • Recheck coverage before switching. A plan may cover one medication and not another. Try the GLP-1 insurance checker.
  • Tell the FDA. If its database does not list the product, report the shortage through the FDA’s public portal.4

What the end of the shortage meant for compounded GLP-1s

It ended the FDA’s enforcement discretion toward compounders making copies of these drugs. The last periods ran out on March 19, 2025 for tirzepatide and May 22, 2025 for semaglutide.5

As of the FDA’s April 1, 2026 update, neither drug is on the shortage list. A state-licensed pharmacy may not regularly make what is essentially a copy of a commercially available drug unless the prescriber documents a significant difference for that patient. A compound with an added ingredient such as vitamin B12 may still count as a copy.5

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness or quality, and says they are for patients whose medical needs an FDA-approved drug cannot meet.10 They are not in the table.

How Zealthy helps you get a GLP-1 prescription filled

A Zealthy provider, a U.S.-licensed physician or nurse practitioner, reviews your intake online and prescribes only what is appropriate for you.

  • Brand-name medication. Wegovy, Zepbound, Ozempic or Mounjaro prescriptions go to your own pharmacy. Ozempic and Mounjaro are approved for type 2 diabetes, not weight loss.2
  • Insurance coordination. Our coordination team submits the prior authorization. When your plan covers the medication, the copay can be as low as $25 a month. Approval is not guaranteed.
  • Compounded options. Compounded semaglutide is $199 a month, or from $106 a month on a 3-month supply. Compounded tirzepatide is $329 a month, or from $216 a month on a 3-month supply. Both ship from a partner pharmacy, shipping included, and are not FDA-approved.

Membership, $39 for the first month and then $135 a month, is required, and medication is billed separately. The GLP-1 pipeline tracker lists medications still in trials.

Get Started

Important safety information

Boxed warning: semaglutide and tirzepatide cause thyroid C-cell tumors in rodents. It is not known whether they do in people. Do not use them if you or a family member has had medullary thyroid carcinoma, if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to the drug. Serious risks include pancreatitis, gallbladder problems, low blood sugar, kidney injury and severe stomach problems.2 The FDA is also adding a warning about a rare eye condition, NAION.11 Common side effects are nausea, diarrhea, vomiting and constipation.2

Full safety information: Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide, tirzepatide.

GLP-1 shortage FAQs

Is Ozempic in shortage right now?

No. On November 18, 2026 the FDA had no shortage record for any Ozempic pen or tablet.1 Ozempic went on the list in August 2022, and the FDA declared the semaglutide injection shortage resolved on February 21, 2025.5,6 A single pharmacy can still be out of a strength.

Is Wegovy still in shortage?

No. Wegovy went on the FDA shortage list in March 2022 and came off when the semaglutide injection shortage was declared resolved on February 21, 2025.5,6 On November 18, 2026 no Wegovy pen, including the 7.2 mg pen, or tablet had a shortage record.1

Is Mounjaro or Zepbound in shortage?

No. Tirzepatide injection went on the shortage list on December 15, 2022. The FDA declared that shortage resolved on October 2, 2024 and confirmed it on December 19, 2024.5,7 On November 18, 2026 openFDA returned no tirzepatide record at all.1

Why are Saxenda and Victoza on the shortage list?

Liraglutide injection has been listed since July 18, 2023.8 Both brands show limited availability. The reason given for Victoza is a shipping delay. Saxenda is being discontinued: Novo Nordisk expects its last wholesaler shipments in late January 2027 and says safety and quality are not the reason.1,9

Why is my pharmacy out of stock if there is no shortage?

Because the FDA list reflects supply reported by manufacturers, not stock at one store. A strength can be off the list while a pharmacy waits on a delivery. Ask when it is expected, try another pharmacy, and message your provider before you run out.

Can I still get compounded semaglutide or tirzepatide?

Yes, with a prescription, but the rules are tighter than during the shortage. A pharmacy may not regularly make what is essentially a copy of a commercially available drug unless the prescriber documents a significant difference for that patient.5 Compounded medications are not FDA-approved. A Zealthy provider prescribes one only when appropriate for you.

How do I report a GLP-1 shortage to the FDA?

Check the FDA’s drug shortage database first. If the product is not listed, anyone can report a new shortage through the FDA’s public portal. Updates on a shortage that is already listed go to drugshortages@fda.hhs.gov.4 Still call your pharmacy or provider about your own prescription.

What does “to be discontinued” mean in the tracker?

The FDA has a record saying the manufacturer is ending that presentation. It is a notice, not a shortage. On November 18, 2026 Saxenda was listed this way, as were Rybelsus® 3 mg, 7 mg and 14 mg tablets, which the FDA’s record says Ozempic tablets will replace.1,8

Sources

  1. FDA. openFDA drug shortages API, records retrieved November 18, 2026. https://open.fda.gov/apis/drug/drugshortages/
  2. DailyMed, National Library of Medicine. Current labels: Ozempic injection https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79; Ozempic tablets https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98; Wegovy https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b; Mounjaro https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0; Zepbound https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b; Saxenda https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143; Victoza https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4; Trulicity https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  3. FDA. openFDA Terms of Service. https://open.fda.gov/terms/
  4. FDA. Drug Shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
  5. FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Updated April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  6. FDA. Declaratory order on the semaglutide injection shortage. February 21, 2025. https://www.fda.gov/media/185526/download
  7. FDA. Declaratory order on the tirzepatide injection shortage. December 19, 2024. https://www.fda.gov/files/drugs/published/2024.12.19_tirzepatide_declaratory_order.pdf
  8. FDA Drug Shortages database, accessed November 18, 2026: Liraglutide Injection https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c; Semaglutide Tablet https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Semaglutide%20Tablet&st=d
  9. Novo Nordisk. Saxenda discontinuation notice. https://www.saxenda.com/
  10. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  11. FDA. Drug Safety Communication on GLP-1 receptor agonists and a rare eye condition (NAION). November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential

The table on this page repeats the FDA’s drug shortage list. It cannot tell you what a particular pharmacy has in stock, and it is not medical advice.

Find out which GLP-1 a provider can prescribe for you

Answer a few health questions online. A licensed provider reviews them, and membership starts at $39 for the first month.

Get Started
A Zealthy provider shown on a phone screen
Your care team

If your dose is hard to find, ask your care team

A U.S.-licensed physician or nurse practitioner reviews your health history, and you can message your care team when a pharmacy cannot fill your strength.

50 statesLicensed providers for members in every state
No appointment neededYour intake is reviewed online, and questions are handled by message
7 days a weekSupport Monday to Friday 9am to 6pm ET, weekends 12pm to 6pm ET

The medical information on this page is reviewed by the Zealthy care team against FDA prescribing information and published clinical trials. It is general education, not personal medical advice.

Zealthy members

What Zealthy members say

One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
Michelle, 33 | Lost 48 pounds
I started semaglutide at the recommendation of my Zealthy provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Michael, 37 | Lost 29 pounds
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and Zealthy was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Susanne, 60 | Lost 33 pounds
Since I started, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
Rachel | Zealthy Member
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
John | Zealthy Member
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Sara | Zealthy Member

Individual results may vary. These are the experiences of Zealthy members and are not a guarantee of any outcome. Medication is prescribed only when a licensed provider finds it appropriate.

Medications

GLP-1 medications Zealthy providers can prescribe

Brand-name or compounded, a licensed provider decides what fits your health history. Our insurance team handles the prior authorization paperwork for brand-name medication.

Compounded medications are prepared by a partner pharmacy for an individual prescription. They are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality. Zealthy membership ($39 for the first month, then $135 a month) is billed separately from medication. A prescription is written only if a licensed provider finds it appropriate.